ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1075 in its research report dated February 02, 2021.

Buy Sun Pharmaceutical Industries; target of Rs 1050: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1050 in its research report dated February 01, 2022.

Buy Sun Pharmaceutical Industries: target of Rs 1000: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1000 in its research report dated January 31, 2022.

Sun Pharma: Traction in specialty impressive

Overall, traction for specialty products for Sun Pharma got a helping hand from the leading products Ilumya, Cequa, Levulan and Absorica

Hold Sun Pharma; target of Rs 775: Emkay Global Financial

Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 775 in its research report dated January 10, 2022.

Buy Sun Pharmaceutical Industries; target of Rs 965: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 965 in its research report dated November 03, 2021.

Hold Sun Pharma; target of Rs 775: Emkay Global Financial

Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 775 in its research report dated November 03, 2021.

Buy Sun Pharma; target of Rs 970: Motilal Oswal

Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 970 in its research report dated Novemer 03, 2021.

Sun Pharma: Fully valued, though performance impressive

Sales of specialty products during the reporting quarter clocked $157 million against $148 million in Q1FY22 and $108 million in Q2FY21.

Ami Organics IPO: A play on critical pharma intermediates

Intermediates are the key area where import dependence is huge, and, hence, a company like Ami Organics is likely to benefit

Cadila: More a COVID hedge in the near term

Cadila's India presence -- at about 45 per cent of sales -- is similar in size as the US business and provides better cash-flow visibility

Buy Sun Pharmaceutical Industries: target of Rs 900: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 900 in its research report dated July 30, 2021.

Sun Pharma: Ilumya illuminates

The specialty segment remains an important part of the Sun Pharma's strategy to scale up business and launch itself into the domain of complex molecules and novel dosage forms

Buy Sun Pharmaceutical Industries; target of Rs 783: Geojit

Geojit is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 783 in its research report dated June 02, 2021.

Hold Sun Pharmaceutical Industries; target of Rs 700: ICICI Direct

ICICI Direct recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 700 in its research report dated May 28, 2021.

Hold Sun Pharma; target of Rs 720: Emkay Global Financial

Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 720 in its research report dated May 28, 2021.

Buy Sun Pharmaceutical Industries: target of Rs 810: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 810 in its research report dated May 27, 2021.

Buy Sun Pharma; target of Rs 830: Motilal Oswal

Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 830 in its research report dated May 28, 2021.

Sun Pharma: Traction in speciality likely to sustain

Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well

Buy Sun Pharmaceutical; target of Rs 786: Dolat Capital Market

Dolat Capital Market is bullish on Sun Pharmaceutical has recommended buy rating on the stock with a target price of Rs 786 in its research report dated May 28, 2021.

Buy Sun Pharmaceutical Industries: target of Rs 700: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 700 in its research report dated April 01, 2021.

Quant Pick - Sun Pharmaceuticals: ICICI Direct

According to ICICI Direct, Buy Sun Pharmaceuticals in range of Rs 625-635 Target: Rs 738 Stop Loss: Rs 570 Time frame: Three months.

Buy Sun Pharmaceutical Industries; target of Rs 700: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 700 in its research report dated January 29, 2021.

Buy Sun Pharmaceutical Industries; target of Rs 672: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 672 in its research report dated February 01, 2021.

Buy Sun Pharmaceutical Industries; target of Rs 675: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 675 in its research report dated January 31, 2021.